concentrations (5-10 lmol/l ATO) in NHL cell lines (Fig 1A) . Further, the addition of BSO to ATO in primary CLL or follicular lymphoma cells did not enhance apoptosis compared with ATO alone. We hypothesized that low intracellular GSH content might explain the higher sensitivity of primary cells to ATO alone and the lower sensitivity to ATO/BSO. GSH levels in CLL cells were 4-5 fold lower compared with levels seen in Ramos or HF1 cells (data not shown).
We investigated whether ATO-induced apoptosis was dependent on Bax translocation. As shown in Fig 2A, ATO alone redistributed Bax from the cytosol to the mitochondria (evident at 6 hours) with release of cytochrome C in Ramos cells. Of note, treatment of cells with combined ATO/BSO did not affect Bax translocation or change in mitochondrial membrane potential ( D w m ), suggesting an alternative cell death pathway.
To Fig 2E) . Altogether, these studies implicate the dependence of Bax and loss of D w m in NHL cells treated with ATO alone, but not with ATO/BSO. With ATO alone, there was increased caspase 8, 9 and caspase 3 cleavage in all lymphoma cell lines at 5-10 lmol/l (Fig 2F) . ATO also induced PARP and BID activation. These findings suggest involvement of both cell death pathways using ATO alone, although with more prominent activation of the intrinsic cascade. In contrast, minimal activation of the intrinsic cascade was observed with ATO/BSO (Fig 2G) . correspondence However, increase in cleaved caspase 7 (Fig 2H) and PARP cleavage was observed following treatment of each of the three cell lines with both ATO and ATO/BSO (Fig 2H) . To further test the dependence of the caspases in ATO-related apoptosis (± BSO), cell lines were pre-treated with the pan-caspase inhibitor, Z-VAD-FMK. Z-VAD-FMK effectively blocked apoptosis with ATO alone in all cell lines, while much less inhibition was seen in ATO/BSO-treated cells (Fig 2I) .
The present study found that ATO alone induced apoptosis in NHL cell lines through ROS, Bax, and caspase-dependent pathways, although relatively high in vitro concentrations of ATO were required for effect. Addition of BSO to ATO Ramos, HF1, and SUDHL4 cells were treated with 2 lmol/l ATO, 100 lmol/l BSO alone, or ATO/BSO combined for 48 h. The percentage of apoptotic cells was determined by AnnexinV/PI staining and analyzed by flow cytometry as described. P values compare ATO + BSO versus ATO and BSO alone. In all three cell lines, there was >75% apoptosis when BSO was added to ATO. P values represent respective concentrations compared with control and single agent alone. (C) ROS was measured in Ramos, HF1, and SUDHL4 cells. Cells were incubated with ATO alone (10 lmol/l) or ATO 2 lmol/l combined with BSO 100 lmol/l for 16 h. Increase in ROS was measured by staining with H2DCF-DA and analyzed by flow cytometry. Peak shift to the right denotes an increase in ROS production. P value for level of ROS production was <0AE05 for control versus ATO/BSO and for ATO/ BSO versus ATO+BSO+NAC for all three cell lines. (D) N-acetylcysteine (NAC) attenuated ATO-and ATO/BSO-induced apoptosis. Ramos, HF1, and SUDHL4 cells were pretreated with NAC 10 mmol/l for 4 h followed by incubation with ATO 10 lmol/l or ATO 2 lmol/l and BSO 100 lmol/l, and in combination with NAC for 48 h. Percentage apoptosis was determined as previously described. P values compared ATO+NAC versus ATO and ATO+BSO+NAC versus ATO+BSO. *P < 0AE05, **P < 0AE01, and ***P < 0AE001. (E) Ramos cells were pre-incubated with 1000 units of catalase following treatment with the indicated concentrations of ATO or ATO/BSO for 48 h. Apoptosis was measured by annexinV/PI staining. (F) Peripheral blood mononuclear cells (PBMC) were isolated from the peripheral blood of three CLL patients and from (G) two patients with follicular lymphoma as described in the text. Cells were incubated with indicated concentrations of ATO or ATO/BSO for 24 h (all CLL cases), 48 h (follicular lymphoma Patient 1), and 72 h (follicular lymphoma Patient #2). Percentage apoptosis was determined as described before. P values compare ATO versus control. *P < 0AE05, **P < 0AE01, and ***P < 0AE001.
resulted in highly synergistic cell death with apoptosis that occurred through a Bax-and caspase-independent pathway. Furthermore, we discovered critical differences between primary lymphoma/leukaemia cells and in vitro cell lines. BSO did not enhance ATO-related cell death in primary cells, which was likely due to higher basal levels of intracellular GSH Mitochondrial and cytosolic fractions were separated as described in the text and analyzed by Western blotting for pro-apoptotic Bax and cytochrome c proteins. Mn-SOD and actin were used as internal controls for mitochondrial and cytosolic extracts, respectively. There was release of cytochrome c from the mitochondria to the cytosol over time with ATO alone, with translocation of Bax to the mitochondria (left panel), while in the presence of BSO, there was no change in mitochondrial Bax or cytosolic cytochrome c, suggesting an alternate cell death pathway. (B) Apoptosis was measured in wild type and Bax )/) /Bak )/) MEFs. Cells were plated the night before the treatment. Cells were treated with the indicated concentrations of ATO and ATO/BSO for 24 h followed by annexinV/PI staining and flow cytometry. (C) SUDHL4 cells were treated with ATO or ATO/BSO for 16 h followed by incubation with 200 nmol/l mitotracker red and 1 lg/ml Hoechst stain for 30 min at 37°C followed by washing with Hanks Balanced Salt Solution and fixed in 3AE7% formaldehyde. Fixed cells were used for confocal microscopy. , and HF1 cells were pre-treated with the pan-caspase inhibitor, Z-VAD-FMK (50 lmol/l) for 4 h, followed by treatment with ATO 10 lmol/l or ATO 2 lmol/l combined with BSO 100 lmol/l for 48 h. Percentage apoptosis was determined by flow cytometry after staining the cells with annexin V/PI. Abbreviations: H, hours; MEFs, mouse embryonic fibroblasts; Mito-Bax, mitochondrial-related Bax. *P < 0AE05, **P < 0AE01, and ***P < 0AE001, unless otherwise indicated. Correspondence
